FDA approved biosimilar pegfilgrastim to decrease the chance of febrile neutropenia in patients with non-myeloid cancers on myelosuppressive chemotherapy

 

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply